首页 › 基金 › SILVERARC CAPITAL MANAGEMENT, LLC › IMNM
SILVERARC CAPITAL MANAGEMENT, LLC 对 IMNM 的持仓历史
IMMUNOME INC · 医疗保健
SILVERARC CAPITAL MANAGEMENT, LLC 在 Q3 2026 的 13F 申报中披露持有 IMNM(IMMUNOME INC)2,092,715 股,市值约 US$45.0M,约占其申报组合的 5.74%,在其申报持仓中市值排名第 5 位。 SILVERARC CAPITAL MANAGEMENT, LLC 最近 11 个申报季度中有 5 个季度披露了 IMNM 持仓,最早可追溯至 Q1 2024。
最后更新: 2026-11-13 · 来源: SEC EDGAR Form 13F-HR
SILVERARC CAPITAL MANAGEMENT, LLC 对 IMNM 的持仓演变
SILVERARC CAPITAL MANAGEMENT, LLC 于 Q1 2024 首次披露 IMNM 持仓:7,489 股(约 US$185K)。 该持仓在 Q3 2026 达到峰值 2,092,715 股,市值约 US$45.0M。 在 5 次申报中,SILVERARC CAPITAL MANAGEMENT, LLC 3 次增持、0 次减持、0 次保持不变。 最近一期申报(Q3 2026)显示持股 2,092,715 股、市值约 US$45.0M,环比增持 75,706 股。。 持仓曾出现大幅变动:Q1 2026 增持约 64% (随后一个季度股价下跌 3%)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q1 2024 | 7.49K | $184.83K | 新进 |
| Q4 2025 | 1.13M | $24.19M | 新进 |
| Q1 2026 | 1.85M | $40.47M | 增持 |
| Q2 2026 | 2.02M | $42.74M | 增持 |
| Q3 2026 | 2.09M | $45.01M | 增持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 IMNM 与 13F 数据
IMNM(IMMUNOME INC)属于医疗保健行业。我们追踪的基金中还有 42 只申报持有 IMNM,申报仓位最大的包括:Redmile Group, LLC (US$104.1M), Enavate Sciences GP, LLC (US$76.6M), Sofinnova Investments, Inc. (US$36.5M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 IMNM 的基金
- Redmile Group, LLC 4.91M 股 · $104.08M · Q2 2026
- Enavate Sciences GP, LLC 3.61M 股 · $76.58M · Q2 2026
- Sofinnova Investments, Inc. 1.72M 股 · $36.45M · Q2 2026
- READYSTATE ASSET MANAGEMENT LP 1.61M 股 · $34.03M · Q2 2026
- Pivotal bioVenture Partners Investment Advisor LLC 732.51K 股 · $15.52M · Q2 2026
- NAN FUNG TRINITY (HK) Ltd 621.08K 股 · $13.36M · Q3 2026
- Parkman Healthcare Partners LLC 594.20K 股 · $12.59M · Q2 2026
更多关于 SILVERARC CAPITAL MANAGEMENT, LLC
常见问题
How long has SILVERARC CAPITAL MANAGEMENT, LLC held IMNM?
SILVERARC CAPITAL MANAGEMENT, LLC has disclosed IMNM holdings in 5 of the last 11 reported quarters, going back to Q1 2024.
What is SILVERARC CAPITAL MANAGEMENT, LLC's current position in IMNM?
As of Q3 2026, SILVERARC CAPITAL MANAGEMENT, LLC holds 2.09M shares of IMNM (IMMUNOME INC), valued at $45.01M, representing 5.74% of its reported portfolio and ranking #5.
Has SILVERARC CAPITAL MANAGEMENT, LLC been buying or selling IMNM?
In the latest 13F filing (Q3 2026), SILVERARC CAPITAL MANAGEMENT, LLC increased its position in IMNM. The position peaked in Q3 2026 at 2.09M shares.
Which other funds hold IMNM?
Other major institutional holders of IMNM include Redmile Group, LLC, Enavate Sciences GP, LLC, Sofinnova Investments, Inc., among 42 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.